Bosutinib
Showing 1 - 25 of 72
Dementia With Lewy Bodies Trial in Washington (Placebo Oral Tablet, Bosutinib Oral Tablet)
Completed
- Dementia With Lewy Bodies
- Placebo Oral Tablet
- Bosutinib Oral Tablet
-
Washington, District of ColumbiaMedStar Georgetown University Hospital
Apr 4, 2022
Condition Vasoregulation Function Endothelium in CML Getting TKI
Recruiting
- Chronic Myeloid Leukaemia
- taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
-
Moscow, Russian Federation
- +1 more
Jan 11, 2023
Describe Real World Use of Bosutinib inSingle Centre in Scotland
Completed
- Myeloid Leukemia
- Bosutinib
-
Glasgow, United Kingdomeatson West of Scotland Cancer Centre
May 3, 2022
NSCLC, Mesothelioma, Bladder Cancer Trial in Augusta (Bosutinib, Pemetrexed)
Completed
- Carcinoma, Non-Small-Cell Lung
- +7 more
- Bosutinib
- Pemetrexed
-
Augusta, GeorgiaAugusta University Georgia Cancer Center
Jun 10, 2022
Healthy Participants Trial in Brussels (Bosutinib capsule)
Completed
- Healthy Participants
- Bosutinib capsule
-
Brussels, Bruxelles-capitale, Région DE, BelgiumBrussels Clinical Research Unit
Feb 9, 2022
Healthy Participants Trial in Groningen, Utrecht (Bosutinib capsule, Bosutinib tablet)
Completed
- Healthy Participants
- Bosutinib capsule
- Bosutinib tablet
-
Groningen, Netherlands
- +1 more
Feb 14, 2022
Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and
Completed
- Leukemia
- No Intervention
-
Cambridge, MassachusettsTakeda
Feb 28, 2023
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
Recruiting
- Metastatic Breast Cancer
- +2 more
- Palbociclib
- +2 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center
Jan 17, 2022
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,
Completed
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- +6 more
- Bosutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 25, 2022
Leukemia, Chronic Myelogenous Trial in Japan (Bosutinib)
Completed
- Leukemia, Chronic Myelogenous
- Bosutinib
-
Toyoake-City, Aichi, Japan
- +20 more
Apr 26, 2022
Landscape and Real-life Treatment Outcomes in Hungary: Analysis
Completed
- Chronic Myeloid Leukaemia
- Bosutinib
- +4 more
-
Budapest, HungaryPfizer
Dec 15, 2022
Chronic Phase-Chronic Myeloid Leukemia Trial in Madrid (Bosutinib 400 MG Monotherapy, Bosutinib 400 MG + Atezolizumab 840 MG in
Recruiting
- Chronic Phase-Chronic Myeloid Leukemia
- Bosutinib 400 MG Monotherapy
- Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection
-
Madrid, SpainHospital Universitario Ramón y Cajal
Mar 8, 2021
Safety And Efficacy Of Bosutinib
Recruiting
- Chronic Myelogenous Leukemia
- Bosutinib
-
Shibuya-ku, Japan(unnamed)
Dec 29, 2020
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission Trial
Recruiting
- Chronic Myeloid Leukemia
- +2 more
- Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
- Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
-
Houston, Texas
- +3 more
Jan 25, 2022
Chronic Myeloid Leukemia Trial in Italy (Bosutinib)
Completed
- Chronic Myeloid Leukemia
- Bosutinib
-
Alessandria, Italy
- +44 more
Feb 2, 2023
Amyotrophic Lateral Sclerosis Trial in Japan (Bosutinib)
Recruiting
- Amyotrophic Lateral Sclerosis
- Bosutinib
-
Kyoto, Japan
- +3 more
Feb 3, 2021
CML Trial in Brussels (200 Mg capsules of bosutinib in Water solution, bosunitib sorbitol, Bosutinib Mannitol)
Completed
- CML
- 200 Mg capsules of bosutinib in Water solution
- +13 more
-
Brussels, BelgiumPfizer Clinical Research Unit
Jul 8, 2020
Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase
Terminated
- Accelerated Phase Chronic Myelogenous Leukemia (CML)
- +3 more
- Axitinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Nov 17, 2020
Chronic Myelogenous Leukemia Trial in Worldwide (Asciminib, Bosutinib)
Active, not recruiting
- Chronic Myelogenous Leukemia
- Asciminib
- Bosutinib
-
Chicago, Illinois
- +87 more
Jan 20, 2023
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia Trial in Moscow
Active, not recruiting
- Chronic Myeloid Leukemia
- +2 more
- Imatinib
- +3 more
-
Moscow, Russian FederationNational Research Center for Hematology
Oct 1, 2020
Recurrent Acute Myeloid Leukemia Trial in Duarte (Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate)
Withdrawn
- Recurrent Acute Myeloid Leukemia
- Bosutinib Monohydrate
- +6 more
-
Duarte, CaliforniaCity of Hope Meidcal Center
Jun 7, 2022
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in Canada (Olaparib, Dasatinib, Nivolumab plus Ipilimumab)
Recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Olaparib
- +13 more
-
Edmonton, Alberta, Canada
- +9 more
Jan 9, 2023
Previously Treated PH + CML Trial in Worldwide (Bosutinib)
Terminated
- Previously Treated PH + CML
- Bosutinib
-
Los Angeles, California
- +47 more
Dec 2, 2021